194032-49-0

Basic information

• Product Name: RaceMic tert-butyl 3,6-diazabicyclo[3.2.1]octane-6-carboxylate
• Synonyms: RaceMic tert-butyl 3,6-diazabicyclo[3.2.1]octane-6-carboxylate;RaceMic tert-butyl 3,6-diazabicyclo[3.2.1]octane-6-carboxylate hydrochloride;(1S,5R)-TERT-BUTYL 3,6-DIAZABICYCLO[3.2.1]OCTANE-6-CARBOXYLATE
• CAS NO: 194032-49-0
• Molecular Formula: C₁₁H₂₀N₂O₂
• Molecular Weight: 212.2887
• Mol File: 194032-49-0.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 295.4±13.0 °C(Predicted)
• Appearance: /
• Density: 1.076±0.06 g/cm3(Predicted)
• PKA: 10.78±0.20(Predicted)
• CAS DataBase Reference: RaceMic tert-butyl 3,6-diazabicyclo[3.2.1]octane-6-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: RaceMic tert-butyl 3,6-diazabicyclo[3.2.1]octane-6-carboxylate(194032-49-0)
• EPA Substance Registry System: RaceMic tert-butyl 3,6-diazabicyclo[3.2.1]octane-6-carboxylate(194032-49-0)

Safety Data

• Hazardous Substances Data: 194032-49-0(Hazardous Substances Data)

Usage

General Description

RaceMic tert-butyl 3,6-diazabicyclo[3.2.1]octane-6-carboxylate is a chemical compound that falls under the category of a carboxylate ester. It is commonly used as a reagent and a catalyst in various chemical reactions. RaceMic tert-butyl 3,6-diazabicyclo[3.2.1]octane-6-carboxylate has a molecular formula of C12H21NO2 and a molecular weight of 211.3 g/mol. RaceMic tert-butyl 3,6-diazabicyclo[3.2.1]octane-6-carboxylate is a white to off-white solid at room temperature and is insoluble in water but soluble in organic solvents. It is also known to be stable under normal conditions, making it a reliable and versatile compound for use in organic synthesis and other chemical applications.

Upstream product

• 848591-67-3 tert-butyl 2,4-diformylpyrrolidine-1-carboxylate 
• 1058737-58-8 tert-butyl 2,4-bis(hydroxymethyl)pyrrolidine-1-carboxylate 
• 49805-30-3 2-azabicyclo[2.2.1.]hept-5-en-3-one 
• 1058737-59-9 tert-butyl 2,4-bis((methylsulfonyloxy)methyl)pyrrolidine-1-carboxylate 
• 188345-71-3 2-(tert-butoxycarbonyl)-2-azabicyclo[2.2.1]hept-5-ene 
• 24424-99-5 di-tert-butyl dicarbonate 
• 848591-68-4 tert-butyl 3-benzyl-3,6-diazabicyclo[3.2.1]octane-6-carboxylate 

Downstream Products

• 1001856-75-2 C₂₁H₂₇N₅O₃ 
• 848591-69-5 3-(6-Phenyl-pyridazin-3-yl)-3,6-diaza-bicyclo[3.2.1]octane-6-carboxylic Acid Tert-Butyl Ester 

Relevant articles and documents

BRIDGED DIAZEPANE OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to bridged diazepane compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

AMIDES OF DIAZABICYCLOOCTANES AND USES THEREOF

The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS).

HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS

A compound of Formula 1: A-C(O)-Cy, wherein A is a diazabicyclic core, containing 7, 8, or 9 ring atoms, and selected from the following: 2,6-diazabicyclo[3.2.0]heptane; 3,6-diazabicyclo[3.ZO]heptane; 2,7-diazabicyclo[4.2.0]octane; 3,7-diazabicyclo[4.2.0]octane; 3,8-diazabicyclo[4.2.0]octane; 2,7-diazabicyclo[3.3.0]octane; 2,7-diazbicyclo[4.3.0]nonane; 2,8-diazbicyclo[4.3.0]nonane; 3,7-diazabicyclo[4.3.0]nonane; 3,8-diazabicyclo[4.3.0]nonane; 3,9-diazabicyclo[4.3.0]nonane; 2,6-diazabicyclo[3.2.1 ]octane; 3,6-diazabicyclo[3.2.1]octane; wherein the diazabicycle is attached as a radical to the depicted carbonyl via either one of the two ring nitrogen atoms, such that the carbonyl forms an amide bond with the ring nitrogen; Cy is a heteroaryi group; The compounds exhibit selectivity for, and bind with high affinity to, neuronal nicotinic receptors of the α402 subtype in the central nervous system (CNS). The compounds and compositions can be used to treat and/or prevent a wide variety of conditions or disorders, particularly CNS disorders. The compounds are believed to: (i) alter the number of nicotinic cholinergic receptors of the brain of the patient, (ii) exhibit neuroprotective effects, and (iii) when employed in effective amounts, not result in appreciable adverse side effects, namely side effects such as significant Increases in blood pressure and heart rate, significant negative effects upon the gastrointestinal tract, and significant effects upon skeletal muscle.